Skip to main content
OpenTrials
Completed

NCT Number: NCT03058848

Evaluation of PKU Start

To evaluate the acceptability, tolerance and effect on metabolic control of PKU Start, a new Phe free protein substitute for the dietary management of PKU in infants from birth.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 week–2 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NHS Greater Glasgow and Clyde, Glasgow, Lanarkshire, United Kingdom

Loading trial locations.

About this study

This is an assessment of ten (10) infants who require a protein restricted diet that is low in Phe. Infants who routinely use a Phe free infant formula as part of their dietary therapy will be recruited for a 28-day assessment of PKU Start, to evaluate tolerance and acceptability.

The outcome of this assessment will be used in a submission to the regulatory authorities, Advisory Committee on Borderline Substances (ACBS), for PKU Start to become reimbursable on prescription in the UK.

The participant's dietitian will advise on an appropriate amount of PKU Start based on individual requirements. Parents/carers will be asked to substitute their usual Phe-free infant formula with PKU Start for one (1) month. The sponsor will supply PKU Start free of charge.

Prior to starting PKU Start, parents/carers will be asked to record information about the infant's usual GI tolerance and feeding pattern for a period of three (3) days, to allow for comparison between their existing formula and PKU Start.

They will be asked to record information about the following:

Stools Vomiting and Spit-up Feed / Fluid Intake and Compliance Phenylalanine Levels Final Evaluation about the presentation of the product, ease of preparation and how PKU Start flowed through the teat of a bottle.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A diagnosis of classical or severe PKU on new-born screening (For the purposes of this study, 'severe' is defined as phe concentrations between 120 and 600 µmol/L at diagnosis)
  • Taking a minimum of one (1) feed of a Phe-free infant formula
  • A minimum period of four (4) weeks from the time of diagnosis to initial approach to parents

Exclusion criteria

  • Diagnosed with mild PKU or hyperphenylalaninaemia (For the purposes of this study, 'mild' is defined as phe concentrations between 120 and 600 µmol/L at diagnosis)
  • Diagnosis of a congenital condition

Treatment and study plan

PKU Start

Dietary Supplement

PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.

The recommended amount of the product for each participant will be determined and prescribed by a dietitian.

Primary outcomes

  1. Product compliance daily diary

    Time frame: Days 1-28

    Quantitative assessments from subject questionnaires that allow evaluation of compliance with the study product, i.e. actual versus prescribed intake.

  2. GI tolerance daily diary

    Time frame: Days 1-28

    Qualitative assessments from subject questionnaires that allow evaluation of the gastro-intestinal tolerance of the study product.

  3. Ease of use questionnaire

    Time frame: Day 29

    Qualitative assessment from subject questionnaire that allows evaluation of the ease of use of the study product.

  4. Daily phenylalanine control

    Time frame: Days 1-28

    Collection of quantitative data regarding phenylalanine control using routine biochemical testing

Sponsors and collaborators

Lead sponsor

Vitaflo International, Ltd

Industry

Registry information

Official study title

A Study to Evaluate the Acceptability of a New Phenylalanine Free Infant Formula for Use in the Dietary Management of Phenylketonuria in Infants From Birth to 2 Year of Age With Regard to Product Tolerance and Adherence.

Acronym: PKU Start

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Feb 23, 2017
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.